Piramal Group

The company aims to raise RS 300 billion in the current financial year, about half of which has been borrowed already, said chief executive officer and managing director Jairam Sridharan

Piramal Finance Ltd (formerly known as Piramal Capital & Housing Finance Ltd) on Friday said the company wants to achieve AUM size of Rs 1.5 lakh crore by 2028. "We want to build a business that is Rs 1.5 lakh crore in AUM, 3 per cent in return on assets and predictable in terms of profitability. We have spoken about that," Piramal Finance MD and CEO Jairam Sridharan said at the listing ceremony at NSE. The company achieved a 17 per cent growth in total Asset Under Management (AUM) from Rs 68,845 crore as of March 31, 2024, to Rs 80,689 crore as of March 31, 2025. The mix of total AUM across retail and wholesale segments improved to 80:20 as of March 31, 2025, from 70:30 as of March 31, 2024. Piramal Finance got listed at the stock exchanges earlier in the day following the merger of Piramal Enterprises with the former. As many as 22,66,77,700 shares of Rs 2 each were listed on stock exchanges at a price of Rs 1,260 a piece. Speaking at the event, Piramal Finance Chairman Anand ...

The drugmaker's revenue fell 9% in Q2FY26 on below-par CDMO performance; company says it faced inconsistent funding in H1FY26

Jairam Sridharan, MD & CEO, Piramal Finance shares the rationale of the entire exercise and the growth roadmap for the upper layer NBFC in a conversation with Aathira Varier and Manojit Saha in Mumbai

A group of investors led by Multiples Equity on Tuesday received approval from the Competition Commission of India (CCI) to acquire stakes in luggage and travel accessories maker VIP Industries. VIP Industries promoters Dilip Piramal and Family in July had announced the sale of up to 32 per cent of their stake in the company to a consortium led by Multiples Equity, an alternative asset management company. The consortium comprises Multiples Private Equity Fund IV (MPEF), Multiples Private Equity Gift Fund IV (MPGF), Samvibhag Securities, Caratlane founder Mithun Padam Sacheti, and his brother, Siddhartha Sacheti. "The proposed combination relates to the acquisition of certain shareholding by Multiples Private Equity Fund IV, Multiples Private Equity Gift Fund IV, Samvibhag Securities Pvt Ltd, Mithun Sacheti and Siddhartha Sacheti in VIP Industries Ltd," the fair trade regulator said in a release. Multiples focuses on core sectors of financial services, pharma & healthcare, consumer

US biotech funding slowdown hits Piramal's CDMO business as company expands sterile injectables facility and maintains long-term growth targets

Piramal Pharma sold 20 per cent of its stake to Carlyle Group in June 2020, in a deal worth ₹3,523 crore

Funds raised through three tranches will be used for onward lending, refinancing, debt repayment and short-term investments, says the Piramal Enterprises NBFC arm

PPL projects a muted FY26 due to global headwinds but aims to double its India consumer health business turnover to Rs 2,000 crore by FY30 through scale and expansion

Piramal Pharma stock was down 4.5 per cent at ₹209 compared to the previous day's close of ₹219.04 on the NSE

Investment banking sources said the Piramal group is open to acquisitions, though it is not involved in any talks

Maharashtra's tax office has contended that the transfer of its pharma business to Piramal Pharma counts as an itemized sale and not a slump sale, the company said

R Subramaniakumar was initially appointed for a period of three years as MD and CEO of the bank in June 2022

Piramal Pharma on Friday said it will pay USD 407,400 to US-based VetDC, Inc to settle a dispute over rejected batches of a product. Piramal Pharma Solutions Inc, a unit of the company, and VetDC, Inc have entered into a settlement agreement for an amount of USD 407,400, the drug maker said in a regulatory filing. VetDC had claimed damages on account of rejection of certain batches of product manufactured and supplied by Piramal Pharma Solutions Inc. "While the company continues to believe that its legal stand is appropriate against claims made by VetDC and maintains that it has defence to VetDC's claims of liabilities and damages, in order to solely avoid continued legal costs and uncertainties of protracted litigation, the Company and VetDC have both decided to settle," Piramal Pharma said. The company shall have no responsibility for any other costs beyond the amount of USD 407,400, it added. "This settlement will not have a significant impact on the financial position of the .

Till 12:35 pm; a combined 32.3 million shares representing 2.43 per cent of total equity of PPL changed hands on the NSE and BSE.

Piramal Pharma is utilising a capex of about USD 85 million for various initiatives, including capacity expansion, maintenance and de-bottlenecking of CDMO sites, in the current fiscal, according to its Chairperson Nandini Piramal. The Mumbai-headquartered firm, which aims to cross USD 2 billion in revenue by FY30, has already invested around USD 30 million in the first half of the ongoing fiscal on the initiatives. "We expect the capex this year to be at a similar level as last year, which is about USD 85 million," Piramal told PTI in an interaction. A part of the capex is planned for the domestic market while some of it would also go into the US business, she added. "Some part of it, around USD 30 million, is maintenance capex, and the rest would go into capacity expansion in Telangana and Dahej (Gujarat) plants and also towards de-bottlenecking of some of the CDMO sites," Piramal noted. The company last week reported over four-fold increase in consolidated net profit at Rs 23 c

Piramal Pharma's company's revenue for the quarter under review stood at Rs 2,242 crore as compared to Rs 1,911 crore which implies an increase of 17 per cent Y-o-Y

Eyeing tripling of Ebitda and bringing down net debt during the same period

Piramal Pharma aims to achieve over $2 billion in revenue by FY30, which implies 2 times growth in revenue compared with FY24

As many as 43.42 million equity shares, representing 3.3 per cent of total equity of the pharma company, had changed hands on the NSE till afternoon